FDA greenlights Therabionic device for at-home cancer treatment

Therabionic GmbH received U.S. FDA humanitarian device exemption (HDE) for its P1 device for at-home treatment of hepatocellular carcinoma, which accounts for 80% of all liver cancers, in patients who have failed first- and second-line therapies.

Related Keywords

Therabionic Gmb , ,Therabionic Gmbh ,Hepatocellular Carcinoma ,Liver Cancer ,Radiofrequency Electromagnetic Fields ,Humanitarian Use Device ,